Health Canada finalises guidance on biosimilars
This article was originally published in Scrip
Health Canada has issued its much-awaited final guidance on the authorisation of subsequent entry biologics (SEBs), also referred to as biosimilars or follow-on biologics in some jurisdictions.
You may also be interested in...
Swissmedic will scale back its review procedure for certain anti-infectives if the indications for which approval is being sought are identical to those approved in the EU or the US.
Based on the operational experience gained using the new international standard for reporting suspected adverse reactions in EudraVigilance, the EU has decided to set a date for its mandatory use.
The UK’s Health Research Authority has agreed in principle to implement a new policy that aims to drive a lasting change in clinical trial transparency. Not everyone is convinced.